EGFR and neoplasm: Activation of c-Met signaling and/or HGF up-regulation in the tumor microenvironment may confer resistance to RTKs-targeting cancer therapies already in clinical use, including epidermal growth factor receptor (EGFR) and v-RAF murine sarcoma viral oncogene homolog B1 (BRAF) kinase inhibitors.